Tripla negatív emlőrák: ki dolgozik rajta

Intézményenként egy kártya. Célpontra vagy országra szűkítheted a listát.

• Minden célpont
• PD-L1 26
• HER2 24
• PD-1 36
• BRCA1 5
• STAT3 1
• STING 0
• EGFR 4
• PI3K 1
• BRCA2 2
• TP53 1
• AKT 0
• PARP 1
• mTOR 0
• TROP2 6
• AR 1
• PTEN 0
• CDK4/6 3
• VEGF 4
• HIF-1 0
• MYC 0
• GPX4 0
• YAP 0
• CTNNB1 0
• JAK 1
• HDAC 0
• MAPK 0
• BCL-2 0
• CXCR4 1
• ERK 0
• NRF2 0
• PPAR 0
• B7-H3 4
• EZH2 0
• FAK 0
• PRMT5 0
• CD47 0
• HSP90 0
• PSMA 4
• IL-6 0
• PIK3CA 2
• CTLA-4 1
• HER3 2
• TNF 0
• COX-2 0
• IGF1R 0
• MEK 0
• FGFR 0
• MDM2 2
• MET 0
• MUC1 3
• NLRP3 0
• PALB2 0
• AMPK 0
• CD40 0
• CSF1R 1
• JNK 0
• METTL3 0
• MMP-9 0
• PKM2 0
• SIRT1 0

15+ intézményből 15, a friss publikációk és a nyitott vizsgálatok szerint rendezve. Ez nem minőségi rangsor.

Funded research projects that name this disease in their title, terms or summary and have not ended yet: who is funded, where, how much and until when. Organisations only; the funder's page has the details.

• NIH NCI · R15

  Mechanotransduction from the tumor microenvironment to the nuclear envelope protein emerin enables nuclear softening during cancer metastasis

  Rowan University· Glassboro, Egyesült Államok· 564 078 USD awarded in fiscal year 2026· until 2029. aug.

• NIH NCI · R44

  Enriching and expanding tumor-reactive CD8 T-cells to treat breast cancer

  Agonox, Inc.· Portland, Egyesült Államok· 977 639 USD awarded in fiscal year 2026· until 2028. aug.

• NIH NCI · K99

  Unlocking Natural Killer cell potential to combat breast cancer metastasis

  University of Colorado Denver· Aurora, Egyesült Államok· 141 337 USD awarded in fiscal year 2026· until 2028. aug.

• NIH NCI · R43

  Analytical Variables and Clinical Utility of AKT1 Mutation Prediction in Breast Cancer Using Deep Learning on Histopathology Images

  Imagenomix Corp.· Brooklyn, Egyesült Államok· 157 826 USD awarded in fiscal year 2026· until 2028. aug.

• NIH NCI · R43

  Stable, highly potent and safe lead peptide drug conjugate for the treatment of triple-negative breast cancer.

  Oncotherapy Solutions, Llc· Seattle, Egyesült Államok· 400 000 USD awarded in fiscal year 2026· until 2027. szept.

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-PF-EF

  DuoLipo-TNP: Dual-Responsive Liposome Platform for Selective Delivery of Triphosphate Nucleotide Prodrugs in Triple-Negative Breast Cancer

  Cardiff University· Cardiff, Egyesült Királyság· EU contribution 260 348 EUR· until 2029. ápr.· 2 countries

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-PF-EF

  Mapping antigenic niches of tumor-infiltrating B cells in triple-negative breast cancer (MAP-BC)

  Karolinska Institutet· Stockholm, Svédország· EU contribution 252 180 EUR· until 2028. dec.

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-SE

  Biomimetic MXene Nanoplatforms for Targeted Combination Therapy of Triple-Negative Breast Cancer (BioMIX)

  Latvijas Universitate· Riga, Lettország· EU contribution 1 147 740 EUR· until 2030. okt.· 12 countries

• European Commission (Horizon Europe) · HORIZON-EIC

  Next generation therapeutic vaccine for targeted cancer treatment (VacciNEXT)

  Basinnov Life Sciences Unipessoal Lda· Lisboa, Portugália· EU contribution 2 827 529 EUR· until 2029. szept.· 3 countries

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-PF-EF

  Co-culture System with Microfluidics and Onboard Sensors for Breast Cancer study (CoSMOS-BC)

  Universidad del Pais Vasco/ Euskal Herriko Unibertsitatea· Leioa, Spanyolország· EU contribution 209 915 EUR· until 2028. aug.

  The disease is named only in the funder's project summary, not in the title.

10 of 463 running projects, newest first. Listed amounts together: 223,8 M USD + 18,5 M EUR.

Sources: NIH RePORTER (U.S. National Institutes of Health, public domain) and CORDIS (European Commission, CC BY 4.0). Changes: filtered by disease, organisations matched to ROR.

Vizsgálatok, amelyek regiszteradata szerint az egyéni résztvevői adatokat (IPD) megosztják.

• A Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Triple-Negative Breast Cancer (MK-2870-011/TroFuse-011)

  NCT06841354· Merck Sharp & Dohme LLC· Forrás

• A Study of Dato-DXd With or Without Durvalumab Versus Investigator's Choice of Therapy in Patients With Stage I-III Triple-negative Breast Cancer Without Pathological Complete Response Following Neoadjuvant Therapy (TROPION-Breast03)

  NCT05629585· AstraZeneca· Forrás

• A Phase III Study of Dato-DXd With or Without Durvalumab Compared With Investigator's Choice of Chemotherapy in Combination With Pembrolizumab in Patients With PD-L1 Positive Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer (TROPION-Breast05)

  NCT06103864· AstraZeneca· Forrás

• A Study of Dato-DXd Versus Investigator's Choice Chemotherapy in Patients With Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer, Who Are Not Candidates for PD-1/PD-L1 Inhibitor Therapy (TROPION-Breast02)

  NCT05374512· AstraZeneca· Forrás

Publikációk erről a betegségről egy MeSH-módszerkifejezés szerint, például szekvenálási vagy képalkotó módszerre.

• Single-Cell Analysis 46
• Organoids 9
• Mendelian Randomization Analysis 2
• CRISPR-Cas Systems 10
• Gene Expression Profiling 110
• Sequence Analysis, RNA 8
• Whole Genome Sequencing 4
• Exome Sequencing 5
• Proteomics 32
• Metabolomics 14
• Mass Spectrometry 3
• Flow Cytometry 11
• Immunohistochemistry 49
• Liquid Biopsy 4
• Circulating Tumor DNA 16
• Xenograft Model Antitumor Assays 254
• Positron-Emission Tomography 13
• Magnetic Resonance Imaging 34
• Machine Learning 28
• Deep Learning 15
• Cohort Studies 21
• Genome-Wide Association Study 3

Megmutatjuk, a betegség mely célpontjait említi az absztrakt, és onnan a rajtuk dolgozókhoz jutsz.